perhexiline maleate

Clinical trial activity

0 trials · 0 clinical orgs · 0 marketing orgs

Mechanism of action

• Carnitine palmitoyltransferase 2INHIBITOR

  CPT2 inhibitor

  It inhibits the mitochondrial enzyme carnitine palmitoyltransferase 1 (CPT-1) and to a lesser extent CPT-2. This causes a shift in myocardial substrate utilisation from long chain fatty acids to carbohydrates, resulting in increased glucose and lactate utilization and increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. Perhexiline maleate was also found to inhibit the activity of Mammalian target of rapamycin complex 1 (mTORC1).

  It inhibits rat heart and liver carnitine palmitoyltransferase 1 (CPT1) (IC50 = 77 and 148 µM, respectively) and rat heart CPT2 (IC50 = 79 µM). It reversibly inhibits Mammalian target of rapamycin complex 1 (mTORC1) at micromolar concentrations.

  • Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) ↗
• Carnitine O-palmitoyltransferase 1, muscle isoformINHIBITOR

  CPT1B inhibitor

  It inhibits the mitochondrial enzyme carnitine palmitoyltransferase 1 (CPT-1) and to a lesser extent CPT-2. This causes a shift in myocardial substrate utilisation from long chain fatty acids to carbohydrates, resulting in increased glucose and lactate utilization and increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. Perhexiline maleate was also found to inhibit the activity of Mammalian target of rapamycin complex 1 (mTORC1).

  It inhibits rat heart and liver carnitine palmitoyltransferase 1 (CPT1) (IC50 = 77 and 148 µM, respectively) and rat heart CPT2 (IC50 = 79 µM). It reversibly inhibits Mammalian target of rapamycin complex 1 (mTORC1) at micromolar concentrations.

  • Carnitine O-palmitoyltransferase 1, muscle isoform (CPT1B) ↗
• Serine/threonine-protein kinase mTORINHIBITOR

  MTOR inhibitor

  It inhibits the mitochondrial enzyme carnitine palmitoyltransferase 1 (CPT-1) and to a lesser extent CPT-2. This causes a shift in myocardial substrate utilisation from long chain fatty acids to carbohydrates, resulting in increased glucose and lactate utilization and increased ATP production for the same O2 consumption as before and consequently increases myocardial efficiency. Perhexiline maleate was also found to inhibit the activity of Mammalian target of rapamycin complex 1 (mTORC1).

  It inhibits rat heart and liver carnitine palmitoyltransferase 1 (CPT1) (IC50 = 77 and 148 µM, respectively) and rat heart CPT2 (IC50 = 79 µM). It reversibly inhibits Mammalian target of rapamycin complex 1 (mTORC1) at micromolar concentrations.

  • Serine/threonine-protein kinase mTOR (MTOR) ↗